FOLR1 and ovarian carcinoma: For instance, Luveltamab tazevibulin (luvelta) is a novel FRα-targeting ADC with a hemiasterlin warhead (DAR4) that showed efficacy in a phase 1 study in 32 patients with relapsed or advanced epithelial ovarian cancer with broad FRα expression, with an ORR of 37.5% [23].